We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-14.51%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.25B
AUM Growth
-$409M
(-25%)
Cap. Flow
-$106M
Cap. Flow
% of AUM
-8.49%
Top 10 Holdings %
Top 10 Hldgs %
50.14%
Holding
212
New
40
Increased
31
Reduced
43
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$43.5M |
| 2 |
Regenxbio
RGNX
|
+$19.9M |
| 3 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$15.6M |
| 4 |
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
|
+$14.2M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$12.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
+$19M |
| 2 |
AGN
Allergan plc
AGN
|
+$18M |
| 3 |
ANI Pharmaceuticals
ANIP
|
+$17.5M |
| 4 |
CBPO
China Biologic Products Holdings, Inc.
CBPO
|
+$17M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$16.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.82% |
| 2 | Miscellaneous | 18.47% |
| 3 | Consumer Staples | 0.59% |
| 4 | Consumer Discretionary | 0.07% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $176M | 14.03% |
14,439,444
| – | – |
|
|
2
Neurocrine Biosciences
NBIX
$15.2B
| $117M | 9.35% |
2,942,967
-341,500
| -10% | -$16.5M |
|
3
Sarepta Therapeutics
SRPT
$2.19B
| $89.4M | 7.14% |
2,784,928
-24,600
| -0.9% | -$835K |
|
4
Travere Therapeutics
TVTX
$5.89B
| $53.6M | 4.28% |
2,647,080
-173,795
| -6% | -$5.15M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $39.4M | 3.14% |
981,759
+146,400
| +18% | +$8M |
|
|
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $38.9M | 3.1% |
+921,800
| New | +$43.5M |
|
|
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
| $31.4M | 2.51% |
1,646,315
-140,000
| -8% | -$3.34M |
|
|
NVRO
8
DELISTED
NEVRO CORP.
NVRO
| $28.1M | 2.25% |
606,811
-192,148
| -24% | -$9.31M |
|
|
GWPH
9
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $27.4M | 2.19% |
+300,000
| New | +$33.4M |
|
10
PUT
PTC Therapeutics
PTCT
$5.48B
| $26.8M | 2.14% |
+1,005,000
| New | +$43M |
|
|
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
| $26.7M | 2.13% |
386,326
+166,093
| +75% | +$15.6M |
|
12
PUT
iShares Russell 2000 ETF
IWM
$76.9B
| $21.8M | 1.74% |
+200,000
| New | +$23.7M |
|
13
Xencor
XNCR
$1.77B
| $21.5M | 1.71% |
1,754,784
-130,000
| -7% | -$2.54M |
|
14
Talphera
TLPH
$61.8M
| $19.1M | 1.53% |
313,203
-15,500
| -5% | -$1.27M |
|
|
RLYP
15
DELISTED
RELYPSA INC COM
RLYP
| $18.3M | 1.46% |
987,942
-151,200
| -13% | -$4.15M |
|
|
LJPC
16
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $18.2M | 1.45% |
654,515
+401,600
| +159% | +$12.7M |
|
|
17
Regenxbio
RGNX
$525M
| $17.2M | 1.37% |
+779,213
| New | +$19.9M |
|
18
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $17.1M | 1.37% |
275,000
-175,000
| -39% | -$13.8M |
|
19
Iovance Biotherapeutics
IOVA
$4.24B
| $17M | 1.36% |
2,955,456
+195,863
| +7% | +$1.53M |
|
|
RXDX
20
DELISTED
Ignyta, Inc.
RXDX
| $17M | 1.35% |
1,931,600
-36,000
| -2% | -$516K |
|
|
CEMP
21
DELISTED
Cempra, Inc.
CEMP
| $16.2M | 1.3% |
582,500
+10,000
| +2% | +$371K |
|
|
PFNX
22
DELISTED
Pfenex Inc.
PFNX
| $14.6M | 1.16% |
971,043
-39,834
| -4% | -$809K |
|
23
uniQure
QURE
$2.99B
| $14.1M | 1.13% |
690,269
+40,000
| +6% | +$1.05M |
|
24
PUT
ProShares Ultra S&P500
SSO
$8.76B
| $11.1M | 0.89% |
1,600,000
+1,200,000
| +300% | +$9.36M |
|
25
Sonida Senior Living
SNDA
$1.91B
| $11.1M | 0.89% |
36,907
-5,793
| -14% | -$1.91M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2015 Portfolio in Review
As of Q3 2015, Perceptive Advisors held 212 positions worth $1.25B, down 25% from $1.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors withdrew a net $106M in Q3 2015, closing 54 positions and reducing 43 holdings. Its most notable exit was ZS PHARMA INC COMS TK (DE), an estimated $19M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in Global Blood Therapeutics, Inc. worth $38.9M.
- Perceptive Advisors's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 921,800 shares worth $38.9M.
- Perceptive Advisors added most to Aravive, Inc. Common Stock in Q3 2015, an estimated $15.6M increase.
- Perceptive Advisors's biggest Q3 2015 reduction was ANI Pharmaceuticals, cutting an estimated $17.5M.
- Perceptive Advisors fully exited ZS PHARMA INC COMS TK (DE) in Q3 2015, selling an estimated $19M.
- Perceptive Advisors's ten largest holdings make up 50% of its $1.25B portfolio in Q3 2015.
- Perceptive Advisors opened 40 new positions and closed 54 in Q3 2015.
- Perceptive Advisors's portfolio value fell 25% quarter-over-quarter to $1.25B.
Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.